Mebias Discovery Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Series A1

  • Latest Deal Amount
  • $631K

  • Investors
  • 7

Mebias Discovery General Information

Description

Developer of pathway-selective drugs intended to identify molecules to bind G-protein coupled receptors to eliminate adverse effects that limit the therapeutic index. The company platform offers a validated and efficient drug discovery technology with well-established mechanisms that present a unique opportunity with lower risk than utilizing traditional techniques to explore new, non-validated mechanisms, enabling healthcare service providers to treat diseases related to neuroscience or pain, metabolic, gastroparesis, and inflammatory-related disorders.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 101 College Street
  • Suite 210
  • New Haven, CT 06510
  • United States
+1 (267)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 101 College Street
  • Suite 210
  • New Haven, CT 06510
  • United States
+1 (267)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mebias Discovery Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series A1) 23-Sep-2022 $631K Completed Clinical Trials - Phase 1
5. Grant 10-Jan-2022 Completed Clinical Trials - Phase 1
4. Grant 29-Oct-2020 Completed Pre-Clinical Trials
3. Early Stage VC 14-Oct-2019 Completed Pre-Clinical Trials
2. Grant 24-Sep-2018 $10M Completed Pre-Clinical Trials
1. Grant 15-Sep-2018 $2M Completed Pre-Clinical Trials
To view Mebias Discovery’s complete valuation and funding history, request access »

Mebias Discovery Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-1
Series A
To view Mebias Discovery’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Mebias Discovery Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of pathway-selective drugs intended to identify molecules to bind G-protein coupled receptors to eliminate adv
Drug Discovery
New Haven, CT
4 As of 2025

Ghent, Belgium
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mebias Discovery Competitors (3)

One of Mebias Discovery’s 3 competitors is Confo Therapeutics, a Venture Capital-Backed company based in Ghent, Belgium.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Confo Therapeutics Venture Capital-Backed Ghent, Belgium
Escient Pharmaceuticals Formerly VC-backed San Diego, CA
Kainova Therapeutics Venture Capital-Backed Montreal, Canada
You’re viewing 3 of 3 competitors. Get the full list »

Mebias Discovery Patents

Mebias Discovery Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260224549-A1 Compounds, compositions, and methods for treating, ameliorating, and/or preventing pain Pending 17-Feb-2023
WO-2024173873-A2 Compounds, compositions, and methods for treating, ameliorating, and/or preventing pain Inactive 17-Feb-2023
WO-2024173873-A3 Compounds, compositions, and methods for treating, ameliorating, and/or preventing pain Inactive 17-Feb-2023
AU-2018211057-A1 Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same Active 17-Jan-2017
AU-2018211057-B2 Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same Active 17-Jan-2017 A61K31/445
To view Mebias Discovery’s complete patent history, request access »

Mebias Discovery Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mebias Discovery Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Life Science Angels Angel Group Minority
Westfield BioVentures Accelerator/Incubator Minority
National Institutes of Health Government
Ben Franklin Technology Partners of Southeastern Pennsylvania Accelerator/Incubator Minority
BioAdvance Capital (Conshohocken) Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Mebias Discovery FAQs

  • When was Mebias Discovery founded?

    Mebias Discovery was founded in 2015.

  • Where is Mebias Discovery headquartered?

    Mebias Discovery is headquartered in New Haven, CT.

  • What is the size of Mebias Discovery?

    Mebias Discovery has 4 total employees.

  • What industry is Mebias Discovery in?

    Mebias Discovery’s primary industry is Drug Discovery.

  • Is Mebias Discovery a private or public company?

    Mebias Discovery is a Private company.

  • What is the current valuation of Mebias Discovery?

    The current valuation of Mebias Discovery is .

  • What is Mebias Discovery’s current revenue?

    The current revenue for Mebias Discovery is .

  • How much funding has Mebias Discovery raised over time?

    Mebias Discovery has raised $4.13M.

  • Who are Mebias Discovery’s investors?

    Life Science Angels, Westfield BioVentures, National Institutes of Health, Ben Franklin Technology Partners of Southeastern Pennsylvania, and BioAdvance Capital (Conshohocken) are 5 of 7 investors who have invested in Mebias Discovery.

  • Who are Mebias Discovery’s competitors?

    Confo Therapeutics, Escient Pharmaceuticals, and Kainova Therapeutics are competitors of Mebias Discovery.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process